News
ATOS
0.8302
+1.87%
0.0152
Weekly Report: what happened at ATOS last week (0203-0207)?
Weekly Report · 5d ago
Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Dow Jones · 02/05 13:00
Weekly Report: what happened at ATOS last week (0127-0131)?
Weekly Report · 02/03 10:41
Atossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy Rating
TipRanks · 01/30 16:25
Atossa Therapeutics issues statement in response to PTAB ruling
TipRanks · 01/30 13:30
Atossa Therapeutics Responds To PTAB Decision On Patent '334, Opts Against Appeal; Will File Continuation Patent Application; New Patent Announced For Sustained Release Compositions Of Endoxifen, Effective Jan 2025
Benzinga · 01/30 13:21
ATOSSA THERAPEUTICS - DECISION HAS NO IMPACT ON FORMULATIONS CURRENTLY IN CLINICAL DEVELOPMENT
Reuters · 01/30 13:17
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Barchart · 01/30 07:17
Weekly Report: what happened at ATOS last week (0120-0124)?
Weekly Report · 01/27 10:43
Atossa Therapeutics Says Z-Endoxifen To Enter Registrational Clinical Trials In 2025; Updates On Progress Expected Q1; Global Business Development Efforts Amplified; Industry Partnerships Deepened; Financial Strength For Long-Term Growth Emphasized
Benzinga · 01/23 13:22
Atossa Therapeutics issues letter to shareholders
TipRanks · 01/23 13:20
ATOSSA THERAPEUTICS ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING 2024 ACCOMPLISHMENTS AND OUTLOOK FOR 2025
Reuters · 01/23 13:15
BRIEF-Atos estimates year-end liquidity at EUR 2.19 billion
Reuters · 01/21 06:17
Weekly Report: what happened at ATOS last week (0113-0117)?
Weekly Report · 01/20 10:37
Weekly Report: what happened at ATOS last week (0106-0110)?
Weekly Report · 01/13 10:38
Atossa Therapeutics ‘applauds’ Surgeon General’s advisory on alcohol
TipRanks · 01/06 14:12
Weekly Report: what happened at ATOS last week (1230-0103)?
Weekly Report · 01/06 10:44
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Barchart · 12/31/2024 08:58
Weekly Report: what happened at ATOS last week (1223-1227)?
Weekly Report · 12/30/2024 10:39
Weekly Report: what happened at ATOS last week (1216-1220)?
Weekly Report · 12/23/2024 10:44
More
Webull provides a variety of real-time ATOS stock news. You can receive the latest news about Atossa Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).